# Danish pharmaceutical giant Novo Nordisk is an object lesson in the risks inherent when investing in highly rated growth companies.

*business · news · 2026-04-16 · The Sunday Times*

## Key points

- Novo Nordisk announced 9,000 layoffs in late 2023, the largest in its history.
- Denmark's economic growth outlook was halved due to Novo Nordisk's decline.
- Wegovy's US price will be cut to around a third of current levels after 2023 negotiations.
- Novo Nordisk's late-stage CagriSema trials showed inferior effectiveness compared to Eli Lilly's rival drug.
- The Novo Nordisk board was overhauled in late 2023, with seven changes and a new CEO appointed.

**Companies:** Novo Nordisk, Eli Lilly
**Countries:** Denmark, United States

[Read the full story on The Sunday Times](https://www.thetimes.com/business/companies-markets/article/buy-shares-novo-nordisk-skwzj3t98)

---

Canonical: https://newsio.io/n/8fe9e186-4ccf-4ec5-9caf-0a08d4901cb8/danish-pharmaceutical-giant-novo-nordisk-is-an-object-lesson-in-the-risks-inhere
Summarized by Newsio from The Sunday Times. https://newsio.io/how-it-works